Known and unknown possibilities of moxonidine

Sychov O.S.,Romanova O.M.,Romanov V.Yu.

Main
Publications
Known and unknown possibilities of moxonidine

September 5, 2022

1110

Cardiology, Rheumatology

Sychov O.S.

Romanova O.M.

Romanov V.Yu.

Keywords :

antihypertensive therapy,

arterial hypertension,

imidazoline receptor agonists,

moxonidine.

Specialities :

Cardiology, Rheumatology

Resume

The article examines the problem of arterial hypertension (AH), the most common non-infectious disease in the world, which has priority in the development of such cardiovascular complications as stroke and myocardial infarction, which cause the increase in disability and premature mortality of the population. A review of current literature data on approaches to the treatment of patients with AH was conducted, with an emphasis on the therapeutic potential of the imidazoline receptor agonist moxonidine, which is currently the most commonly used antihypertensive drug with a central mechanism of action. It is noted that the necessary requirements for prescribing antihypertensive drugs should be their high antihypertensive efficacy, organ protection, synergistic interaction with other classes of antihypertensive drugs, good tolerability, positive or at least neutral effect on lipid and carbohydrate metabolism. A study of the properties of moxonidine on a fairly large sample of patients with AH and associated metabolic disorders showed high antihypertensive effectiveness of the drug both as part of combined therapy and separately.

References

1. Williams B., Mancia G., Spiering W., Rosei E.A. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J., 39(33): 3021–3104. doi.org/10.1093/eurheartj/ehy339.
2. Mancia G., Grassi G. (2014) The autonomic nervous system and hypertension. Circ. Res., 114(11): 1804–1814. doi: 10.1161/CIRCRESAHA.114.302524.
3. Karlafti E.F. (2013) Effect of moxnidine on sympathetic nervous system activity: An update on metabolism, cardio and target-organ protection. J. Pharm. Bioallied. Sci., 5(4): 253–256. doi:10.4103/0975-7406.120067.
4. Chazova I.E., Schlaich M.P. (2013) Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Inter. J. Hyper. dx.doi.org/10.1155/2013/541689.
5. Waters J. et al. (1999) Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension — results of the TOPIC (Trial Of Physiotens In Combination) Study. J. Clin. Basic Cardiol., 2(2): 219–224.
6. Sharma A.M., Wagner T., Marsalek P. (2004) Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J. Hum. Hypertens., 18(9): 669–675. doi: 10.1038/sj.jhh.1001676.
7. Рудик Ю.С. (2017) Моксонідин в современном лечении артериальной гипертензии Рац. фармакотер., 3(44): 5–11.
8. Ozkurt Z.N., Ebinç F.A., Ucardag D. (2008) Effects of Sympatholytic Therapy with Moxonidine on Serum Adiponectin Levels in Hypertensive Women. J. Int. Med. Res., 36: 80–87.
9. Chazova I.E., Almazov V.A., Shlyakhto E.V. (2006) Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin (ALMAZ). Diabetes Obes. Metab., 8: 456–465.
10. Al Kibira G.M. (2020) Prevalence and trends of chronic kidney disease and its factors among US adults: An analysis of NHANES 2003-18. Prev. Med. Rep., 20, 101193. doi.org/10.1016/j.pmedr.2020.101193.
11. Vonend O. et al. (2003) Moxonidine treatment of hypertensive patients with advanced renal failure. J. Hypert., 21(9): 1709–1717. doi:10.1097/01.hjh/0000084733.53355.c3.
12. Hausberg M. et al. (2010) Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J. Hypertension, 28(9): 1920–1927.
13. Littlewood K.J. (2007) Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advances renal failure: a cost-effectiveness analysis. BMC Nephrol., 8: 9. doi:10.1186/1471-2369-8-9.
14. Deftereos S. (2013) Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am. J. Cardiol., 112(5): 684–687. doi: 10.1016/j.amjcard.2013.04.049.
15. Giannopoulos G. et al. (2014) Central sympathetic inhibition to reduce postabblation atrial fibrillation recurrences in hypertensive patients: a randomized controlled study. Circulation, 130(16): 1346–1352.
16. Dudinskaya E., Tkacheva O., Bazaeva E. et al. (2021) Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study. Cardiovasc. Drugs Ther. doi: 10.1007/s10557-021-07235-6.
17. Вороненко Н.Ю. (2013) Гормон жирової тканини адипонектин і його біологічна роль у здорових жінок і пацієнток репродуктивного віку із метаболічним синдромом. Укр. мед. часопоис, 4(96): 142–145.
18. Topal E. (2006) The effect of moxonidine on endothelial dysfunction in methabolic syndrome. Am. J. Cardiovasc. drugs, 6(5): 343–348.